Medical Cannabis Company Better Is Suing InterCure For 35M - Intercure - Benzinga
| INCR Stock | ILS 493.00 1.00 0.20% |
About 62% of Intercure's investor base is looking to short. The analysis of current outlook of investing in Intercure suggests that many traders are alarmed regarding Intercure's prospects. The current market sentiment, together with Intercure's historical and current headlines, can help investors time the market. In addition, many technical investors use Intercure stock news signals to limit their universe of possible portfolio assets.
Intercure |
Medical Cannabis Company Better Is Suing InterCure For 35M - Intercure Benzinga
Read at news.google.com
 |
Intercure Fundamental Analysis
We analyze Intercure's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intercure using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intercure based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Equity
Return On Equity Comparative Analysis
Intercure is currently under evaluation in return on equity category among its peers. Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Intercure Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Intercure stock to make a market-neutral strategy. Peer analysis of Intercure could also be used in its relative valuation, which is a method of valuing Intercure by comparing valuation metrics with similar companies.
Peers
Intercure Related Equities
| TGTR | Together Startup | 0.39 | ||||
| DLEKG | Delek | 0.27 | ||||
| TEVA | Teva Pharmaceutical | 1.06 | ||||
| ELAL | El Al | 3.58 |
Complementary Tools for Intercure Stock analysis
When running Intercure's price analysis, check to measure Intercure's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intercure is operating at the current time. Most of Intercure's value examination focuses on studying past and present price action to predict the probability of Intercure's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intercure's price. Additionally, you may evaluate how the addition of Intercure to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Stocks Directory Find actively traded stocks across global markets |